SYMPOSIA

More documents

Recommendations

Info

NOVEMBER 25, 2011 FRIDAY 18.30-20.30 PS-16: Marijuana; from mellow to madness Co-chairs: Mohamed Husain Habil, Malaysia - Zehra Arıkan, Türkiye SCIENTIFIC PROGRAM What is prevalence of cannabis dependence in Türkiye? Hakan Coşkunol, Türkiye The effect of cannabis use on cognitive functions Cüneyt Evren, Türkiye The differences of marijuana psychosis from other substance induced psychoses Mükerrem Güven, Türkiye Pharmacological treatment of cannabis psychosis Ömer Geçici, Türkiye Selective serotonin reuptake inhibitors (SSRIs) in the treatment of cannabis dependence Musa Tosun, Türkiye Pharmacological drug treatment of substance-induced psychosis, Osman Vırıt, Türkiye drug interactions, and considerations ABBREVIATIONS OC Opening Conference KL Lecture PS Symposium MD Debate JS Joint Symposium KC Course WS Workshop HALL B
09.00-10.30 PS-10: Will glutamatergic modulators be a target for the future therapy of depression? Co-chairs: Cyril Höschl, Czech Republic - Glen Baker, Canada HALL C Treatment with traditional antidepressants and related problems Ayşegül YIldız, Türkiye Glutamatergic system and its importance in the neurobiology of depression Feyza Arıcıoğlu, Türkiye Glutamatergic system and genetic markers associated with Hasan Herken, Türkiye antidepressant treatment Ketamine and other glutamatergic modulators as an antidepressant Serdar Dursun, Canada Do atypical antipsychotics have any glutamatergic effect? Kemal Yazıcı, Türkiye 10.30 - 11.00 COFFEE BREAK 11.00-12.30 PS-12: Vitamin and mineral supplementation in treatment of childhood psychiatric disorders Co-chairs: Tümer Türkbay - Özgür Öner, Türkiye Iron supplementation Ayhan Bilgiç, Türkiye Zinc supplementation Ebru Kültür Çengel, Türkiye Calcium and Vitamin D supplementation Ömer Faruk Akça, Türkiye Cholesterol and Omega 3 fatty acids supplementation Sabri Hergüner, Türkiye Vitamin B 12 and folate supplementation Burak Doğangün, Türkiye Antioxidant vitamin supplementation Betül Mazlum, Türkiye 12.30 - 13.30 LUNCH 16.00 - 16.30 COFFEE BREAK 16.30-18.00 PS-15: Depression and pain Chairperson: Selçuk Kırlı, Türkiye Epidemiology of pain in depression Saygın Eker, Türkiye Clinical characteristics and mechanism of pain in depression Selçuk Kırlı, Türkiye Interaction of pain and depression in terms of clinical characteristics Yusuf Sivrioğlu, Türkiye and mechanism Impact of pain on treatment in depression Cengiz Akkaya, Türkiye 18.00 - 18.30 COFFEE BREAK NOVEMBER 25, 2011 FRIDAY 18.30-20.30 PS-17: Overcoming treatment resistance: An update Co-chairs: Orhan Doğan- Sefa Saygılı, Türkiye SCIENTIFIC PROGRAM Treatment resistant psychiatric disorders and comorbidities Tunç Alkın, Türkiye Treatment resistant psychiatric disorders and trauma history M. Akif Ersoy, Türkiye Strategies in treatment resistant psychotic disorders M. Emin Ceylan, Türkiye Strategies in treatment resistant depression Selçuk Aslan, Türkiye Strategies in treatment resistant panic disorders Erhan Bayraktar, Türkiye Psychosocial interventions in resistance to treatment Mustafa Yıldız, Türkiye
Page 1 and 2: With Contributions of
Page 3 and 4: Turkish Association for Psychopharm
Page 5 and 6: Nihat ALPAY Rüstem AŞKIN Ömer AY
Page 7 and 8: NOVEMBER 23, 2011 WEDNESDAY TIME HA
Page 9 and 10: NOVEMBER 25, 2011 FRIDAY AT A GLANC
Page 11 and 12: 13.30 15.00-16.00 17.30-19.30 17.30
Page 13 and 14: 09.00-10.30 PS-04: Adult attention
Page 15 and 16: 20.30-22.30 KC-01: Biostatistics -
Page 17: 09.00-10.30 PS-09: From preclinical
Page 21 and 22: 09.00-10.30 JS-05: Indian Psychiatr
Page 23 and 24: NOVEMBER 26, 2011 SATURDAY 09.00-10
Page 25 and 26: NOVEMBER 27, 2011 SUNDAY 09.00-10.3
Page 27 and 28: Author(s) Abstracts of the Invited
Page 29 and 30: Author(s) Abstracts of the Invited
Page 31 and 32: Author(s) Poster Presentation 16 A.
Page 33 and 34: Author(s) Poster Presentation 60 Ba
Page 35: Author(s) Poster Presentation 108 O
Page 38 and 39: Abstracts of the Invited Speakers O
Page 40 and 41: Abstracts of the Invited Speakers p
Page 42 and 43: Abstracts of the Invited Speakers D
Page 44 and 45: Abstracts of the Invited Speakers R
Page 46 and 47: Abstracts of the Invited Speakers [
Page 48 and 49: Abstracts of the Invited Speakers H
Page 50 and 51: Abstracts of the Invited Speakers m
Page 56 and 57: Abstracts of the Invited Speakers d
Page 58 and 59: Abstracts of the Invited Speakers e
Page 60 and 61: Abstracts of the Invited Speakers d
Page 62 and 63: Abstracts of the Invited Speakers S
Page 64 and 65: Abstracts of the Invited Speakers o
Page 66 and 67: Abstracts of the Invited Speakers N
Page 68 and 69:
Abstracts of the Invited Speakers I
Page 70 and 71:
Abstracts of the Invited Speakers E
Page 72 and 73:
Abstracts of the Invited Speakers G
Page 74 and 75:
Abstracts of the Invited Speakers T
Page 76 and 77:
Abstracts of the Invited Speakers A
Page 78 and 79:
Abstracts of the Invited Speakers l
Page 80 and 81:
Abstracts of the Invited Speakers E
Page 82 and 83:
Abstracts of the Invited Speakers R
Page 84 and 85:
Abstracts of the Invited Speakers i
Page 86 and 87:
Abstracts of the Invited Speakers
Page 88 and 89:
Page 90 and 91:
Abstracts of the Invited Speakers A
Page 92 and 93:
Abstracts of the Invited Speakers P
Page 94 and 95:
Abstracts of the Invited Speakers [
Page 96 and 97:
Page 98 and 99:
Abstracts of the Invited Speakers O
Page 100 and 101:
Abstracts of the Invited Speakers T
Page 102 and 103:
Abstracts of the Invited Speakers e
Page 104 and 105:
Abstracts of the Invited Speakers o
Page 106 and 107:
Abstracts of the Invited Speakers S
Page 108 and 109:
Abstracts of the Invited Speakers C
Page 110 and 111:
Abstracts of the Invited Speakers [
Page 112 and 113:
Abstracts of Oral Presentations [SO
Page 114 and 115:
Abstracts of Oral Presentations Mat
Page 116 and 117:
Abstracts of Oral Presentations wit
Page 118 and 119:
Abstracts of Oral Presentations pat
Page 120 and 121:
Abstracts of Oral Presentations ade
Page 122 and 123:
Abstracts of Oral Presentations eff
Page 124 and 125:
Turkish Association for Psychopharm
Page 126 and 127:
Poster Presentations behavior by ex
Page 128 and 129:
Poster Presentations [PP-005] Ref.
Page 130 and 131:
Poster Presentations fulfilling the
Page 132 and 133:
Page 134 and 135:
Poster Presentations eating disorde
Page 136 and 137:
Poster Presentations Conclusion: Th
Page 138 and 139:
Poster Presentations had no treatme
Page 140 and 141:
Poster Presentations 80 mg/day (dos
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Poster Presentations Based on the r
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Poster Presentations study, the Cro
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Poster Presentations motivations fo
Page 170 and 171:
Page 172 and 173:
Poster Presentations 4. Şükrü Ka
Page 174 and 175:
Page 176 and 177:
Poster Presentations References: 1.
Page 178 and 179:
Poster Presentations when meeting a
Page 180 and 181:
Poster Presentations MADRS and HAM-
Page 182 and 183:
Poster Presentations in terms of co
Page 184 and 185:
Poster Presentations schizophrenia
Page 186 and 187:
Poster Presentations ascending dopa
Page 188 and 189:
Poster Presentations study. The inc
Page 190 and 191:
Poster Presentations and Spaniards.
Page 192 and 193:
Poster Presentations patients, and
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Poster Presentations 22.7%, bipolar
Page 202 and 203:
Poster Presentations future, we exp
Page 204 and 205:
Poster Presentations of action, ami
Page 206 and 207:
Poster Presentations pharmacologica
Page 208 and 209:
(±)-3-4-methylenedioxymethamphetam
Page 210 and 211:
Panic symptoms S122 Paroxetine S156
Page 212 and 213:
Etli T. S162 Evren C. S80, S154, S1
show all

SYMPOSIA

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?